Failure to Monitor Anticoagulant Therapy for Adverse Effects
Summary
The facility failed to ensure that the drug regimens for two residents were free from unnecessary drugs by not ensuring adequate monitoring for adverse effects related to anticoagulant therapy. One resident was admitted with diagnoses including epilepsy, heart failure, and GERD, and had intact cognition and capacity to make decisions. The resident’s order summary included rivaroxaban 20 mg by mouth in the evening for DVT prophylaxis, but the order summary and MAR did not include monitoring for adverse effects related to rivaroxaban. The care plan addressed risk for bleeding and spontaneous bruising with daily skin inspection and reporting unusual bleeding or bruising, but no medication-specific monitoring order was present. A second resident was admitted with diagnoses including cerebral infarction, paroxysmal atrial fibrillation, and long-term use of anticoagulants, and also had capacity and intact cognition. The resident’s order summary included warfarin sodium 7 mg by mouth in the evening for DVT prophylaxis, but the order summary and MAR did not include monitoring for adverse effects related to warfarin sodium. The care plan again addressed risk for bleeding and spontaneous bruising with daily skin inspection and reporting unusual bleeding or bruising, but there was no order for warfarin-specific monitoring. During interview, RN 1 stated there was no order for monitoring for adverse effects for rivaroxaban on one resident and no order for warfarin sodium on the other resident. The DON stated licensed staff should have obtained orders for monitoring for adverse effects for both anticoagulants and stated the medications could not be treated the same because each had more potent chemicals and different adverse effect concerns. The DON also stated the failure to monitor for adverse effects of rivaroxaban and warfarin sodium could potentially lead to severe bleeding that could lead to death, and stated the facility’s Anticoagulation-Clinical Protocol was not followed. The facility policy required physician collaboration with nursing staff and monitoring for possible complications in individuals being anticoagulated, and the provided prescribing information for both medications included bleeding warnings.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.